Tags : Nivestym

Pfizer’s Nivestym (filgrastim-aafi, biosmilar) Receives the US FDA Approval for

Shots: The approval is based on non-inferiority data demonstrating biosimilarity between Nivestym and the reference product, Neupogen (filgrastim) Pfizer has received the US FDA’s fourth approvals for its biosimilar including Nivestym and will be available at a discount of wholesale acquisition cost (WAC) of Neupogen Nivestym (filgrastim-aafi, Neupogen) is a mAb, indicated to decrease the […]Read More